Linoleic Acid
CAS 60-33-3
Linoleic Acid (CAS 60-33-3) is a Phase 2 pharmaceutical compound with 16 bioactivity targets and 8 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 28552.84896551724 nM | 28 | - |
| - | Potency | 28198.399999999998 nM | 27 | - |
| - | EC50 | 13050.589999999998 nM | 11 | - |
| - | Kd | 25002.4 nM | 2 | - |
| - | Ki | 8050 nM | 2 | - |
| - | MIC | 4 ug.mL-1 | 1 | - |
| Prostaglandin G/H synthase 1 Enzyme |
IC50 | 4.89 | - | Homo sapiens |
| Aromatase Enzyme |
IC50 | 4.32 | - | Homo sapiens |
| Aldo-keto reductase family 1 member C3 Enzyme |
IC50 | 6.16 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor |
Kd | 8.32 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor |
IC50 | 5.21 | - | Homo sapiens |
| Fatty acid-binding protein, adipocyte Cytosolic other |
IC50 | 6 | - | Homo sapiens |
| Fatty acid-binding protein, heart Cytosolic other |
Kd | 9.7 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor delta Nuclear hormone receptor |
IC50 | 5 | - | Homo sapiens |
| Free fatty acid receptor 1 GPCR |
EC50 | 5.7 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily B member 1 Ion channel |
EC50 | 5.6 | - | Homo sapiens |
| Adenosine receptor A1 GPCR |
IC50 | 4.19 | - | Rattus norvegicus |
| Seed linoleate 13S-lipoxygenase-1 Enzyme |
IC50 | 6 | - | Glycine max |
| Tissue factor Membrane receptor |
IC50 | 4.39 | - | Homo sapiens |
| Prostaglandin G/H synthase 2 Enzyme |
IC50 | 4.03 | - | Ovis aries |
| Free fatty acid receptor 4 GPCR |
EC50 | 5.89 | - | Homo sapiens |
| Nuclear receptor subfamily 4 group A member 2 Nuclear other |
Kd | 4.3 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Regurgitation | 12 | 72.984 | 10067171 |
| Oropharyngeal discomfort | 12 | 62.057 | 10068318 |
| Vitamin B12 deficiency | 12 | 61.326 | 10047609 |
| Eructation | 12 | 57.475 | 10015137 |
| Hepatotoxicity | 16 | 55.974 | 10019851 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| FFA1 receptor FFAR1 |
Full agonist | 4.400000095367432 pEC50 | 12496284|12565875|12629551 |
| FFA4 receptor FFAR4 |
Full agonist | 5.89 pEC50 | 16702987 |
| Hepatocyte nuclear factor-4-α HNF4A |
Full agonist | - | 19440305 |
| K 2P 10.1 KCNK10 |
Activator | - | 10880510 |
| K v 2.1 KCNB1 |
Activator | 5.6 pEC50 | 11546665 |
| K v 2.1 KCNB1 |
Channel blocker | 5.1 pIC50 | 11546665 |
| Peroxisome proliferator-activated receptor-γ PPARG |
Full agonist | 5.3 pKd | 11301062|14717706 |
| TRPM8 TRPM8 |
Channel blocker | - | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| LINOLEIC ACID | 6400 | SU | MTHSPL |
| linoleic acid | 6400 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Linoleic Acid used for in pharmaceutical contexts?
Linoleic Acid (CAS 60-33-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Linoleic Acid?
Linoleic Acid has 8 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Regurgitation, Oropharyngeal discomfort, Vitamin B12 deficiency, Eructation, Hepatotoxicity. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Linoleic Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Linoleic Acid with EU status "permitted".
What clinical phase is Linoleic Acid in?
Linoleic Acid is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Linoleic Acid?
Linoleic Acid has 22 bioactivity rows in this page query. Rendered target entries include Prostaglandin G/H synthase 1, Aromatase, Aldo-keto reductase family 1 member C3, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma.